Ipca Laboratories has informed that vide its letter dated 24th August, 2019, it had intimated about US FDA inspection of our Piparia (Silvassa) formulations manufacturing unit from 19th August, 2019 to 23rd August, 2019 which resulted into 3 observations under USFDA Form 483. It has now received a communication from US FDA that they have determined the inspection classification of this manufacturing facility as ‘Official Action Indicated (OAI)’ and that that this facility is considered to be in an unacceptable state of compliance with regards to current good manufacturing practice (CGMP). Since this manufacturing facility is already under US FDA import alert and presently not doing any US business, this will have no impact on Company's current on-going business activities.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1904.65 |
| Dr. Reddys Labs. | 1374.55 |
| Cipla | 1458.45 |
| Zydus Lifesciences | 1141.00 |
| Lupin | 2476.10 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: